StriderDCT is pleased to share that it has signed a Memorandum of Understanding (MoU) with Artificial Brain to jointly develop Quantum-Powered AI solutions for Clinical Research.

StriderDCT brings deep domain expertise in decentralized and technology-enabled clinical trials, with a strong focus on quality, compliance, and patient-centric execution.

Artificial Brain contributes advanced capabilities in Quantum-Powered AI and data intelligence, with a proven track record of translating frontier technologies into scalable, real-world systems.

As clinical research grows increasingly complex, the shift toward intelligent, data-driven platforms is no longer optional. Quantum-Powered AI is becoming critical for improving efficiency, data quality, decision-making, and overall trial outcomes.

Through this collaboration, the aim is to build Quantum-Powered AI platforms that help Indian and global pharmaceutical and research organizations accelerate development timelines, reduce operational friction, and unlock deeper insights from clinical data, enabling faster and more cost-effective delivery of therapies to patients worldwide.

StriderDCT and Artificial Brain look forward to building the future of intelligent clinical research together.

Contact us for decentralized clinical trial solutions.